Amarantus Therapeutics Inc. Appoints Dr. Robert J. Zimmerman as Chief Development Officer 0
Amarantus Therapeutics Inc. Appoints Dr. Robert J. Zimmerman as Chief Development Officer
Amarantus Therapeutics, Inc., a privately-held biotechnology company developing first-in-class disease-modifying treatments that address the underlying cause of cell death, today announced the appointment of Robert J. Zimmerman, S.D., as a consulting Chief Development Officer. In his consulting role, he will help to oversee the development of Amarantus’ lead candidate, AMRS001 for the treatment …
Read more on SYS-CON Media

